Investigational Drug May Block Advance of Type 1 Diabetes

The experimental drug teplizumab shows promise for blocking the advance of type 1 diabetes in its earliest stages.

The results of a Phase 2 study show this new agent was strikingly effective over a period of two years in about half of the patients participating in the trial.

John Schieszer has the latest on the study findings in today's Medical Minute.

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters